MIRM vs. ICPT, CDMO, UROV, NGM, DRRX, ALPN, NUVL, ALKS, PRGO, and CRNX
Should you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Intercept Pharmaceuticals (ICPT), Avid Bioservices (CDMO), Urovant Sciences (UROV), NGM Biopharmaceuticals (NGM), DURECT (DRRX), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector.
Mirum Pharmaceuticals (NASDAQ:MIRM) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
Mirum Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.
83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. 22.9% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 6.2% of Intercept Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Intercept Pharmaceuticals received 956 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 72.37% of users gave Mirum Pharmaceuticals an outperform vote while only 72.27% of users gave Intercept Pharmaceuticals an outperform vote.
In the previous week, Mirum Pharmaceuticals had 8 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 1 mentions for Intercept Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.87 beat Intercept Pharmaceuticals' score of 0.30 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.
Mirum Pharmaceuticals presently has a consensus target price of $49.73, indicating a potential upside of 106.94%. Intercept Pharmaceuticals has a consensus target price of $19.00, indicating a potential upside of 0.00%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than Intercept Pharmaceuticals.
Intercept Pharmaceuticals has a net margin of -19.39% compared to Mirum Pharmaceuticals' net margin of -69.67%. Mirum Pharmaceuticals' return on equity of -56.46% beat Intercept Pharmaceuticals' return on equity.
Intercept Pharmaceuticals has higher revenue and earnings than Mirum Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Mirum Pharmaceuticals beats Intercept Pharmaceuticals on 12 of the 19 factors compared between the two stocks.
Get Mirum Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mirum Pharmaceuticals Competitors List
Related Companies and Tools
